Genetics affects functions of gut microbiome

New research from Cornell scientists is exploring how human genetics impacts functions of the gut microbiome, and is expanding awareness of the role human genetics plays in shaping the microbiome.
The trillions of individual organisms constituting a person’s gut microbiome greatly impact metabolic function, disease and overall health. What has been less clear is how and to what extent the gut microbiome is, in turn, shaped by the genome of its human host.
Ilana Brito, assistant professor and Mong Family Sesquicentennial Faculty Fellow in the Nancy E. and Peter C. Meinig School of Biomedical Engineering, and her coauthors took a novel approach to examining host-microbiome genetic interactions and were able to show many instances where a human host’s genetic makeup directly affected the functional performance of the gut microbiome.
Their paper, “Collective Effects of Human Genomic Variation on Microbiome Function,” was published March 9 in the journal Scientific Reports. The study was a cross-college collaboration that combined Brito’s knowledge of the microbiome with faculty expertise in genetic variation and statistical methodology, respectively, from Andrew Clark, the Jacob Gould Schurman Professor of Population Genetics in the College of Arts and Sciences; and Martin Wells, the Charles A. Alexander Professor of Statistical Sciences in the Department of Information Science.
“When a disease or phenotype is caused by a single genetic mutation it can be a relatively straightforward process to find the gene responsible,” Brito said. But just as often, an entire suite of genes can interact to result in disease or other phenotypic expression, a much more complex mechanism. Within the human genome there are many sequential variations from person to person and even within paired chromosomes of the same person.
When a variation is produced by the substitution of a single nucleotide, this is called single nucleotide polymorphism (SNP). Using a unique computational and modeling approach, Brito’s team was able to identify SNPs that correlated with microbiome-associated traits, disorders and cancers. In other words, they were able to show direct effects of the human genome on the functions of the gut microbiome.

Read more →

Recreational marijuana access reduces demand for prescription drugs

Legalization of recreational marijuana reduces demand for costly prescription drugs through state Medicaid programs, according to an analysis by a Cornell researcher and a collaborator.
When states legalize marijuana, the volume of prescriptions within the drug classes that align with the medical indications for pain, depression, anxiety, sleep, psychosis and seizures significantly decline, the researchers found.
Shyam Raman, a doctoral student in the Cornell Jeb E. Brooks School of Public Policy, and Indiana University doctoral student Ashley Bradford conducted the research. Their article, “Recreational Cannabis Legalizations Associated with Reductions in Prescription Drug Utilizations Among Medicaid Enrollees,” published April 15 in the journal Health Economics.
Most cannabis research has focused on the impact of medical marijuana on demand for prescription drugs or the impact of recreational use legalization on opioid demand. This is among the first studies to focus on the impact of legal personal-use cannabis on a broad range of prescription drugs.
“These results have important implications,” Raman said. “The reductions in drug utilization that we find could lead to significant cost savings for state Medicaid programs. The results also indicate an opportunity to reduce the harm that can come with the dangerous side effects associated with some prescription drugs.”
Raman and Bradford based their study on an analysis of data retrieved from the Centers for Medicare and Medicaid Services in all 50 states from 2011 to 2019, a period that saw growth in the number of states permitting personal use of marijuana.
About 40 states have legalized medical marijuana that must be prescribed by a doctor. So far, about 20 states have legalized personal-use cannabis for all adults, but that number is likely to rise. In those states, Raman and Bradford found a meaningful change in the demand for drugs used to treat sleep and anxiety disorders but no real impact on drugs used to treat nausea.
Raman and Bradford caution that cannabis use is not itself without harm, noting the many studies that associate it with a potential triggering of anxiety and psychoses such as schizophrenia. Also, patients who use marijuana to treat their medical conditions may be shifting away from visiting their doctor and therein creating discontinuities in primary care.
Story Source:
Materials provided by Cornell University. Original written by Jim Hanchett, courtesy of the Cornell Chronicle. Note: Content may be edited for style and length.

Read more →

Bacterial soundtracks revealed by graphene membrane

Have you ever wondered if bacteria make distinctive sounds? If we could listen to bacteria, we would be able to know whether they are alive or not. When bacteria are killed using an antibiotic, those sounds would stop — unless of course the bacteria are resistant to the antibiotic. This is exactly what a team of researchers from TU Delft , led by dr. Farbod Alijani, now have managed to do: they captured low-level noise of a single bacterium using graphene. Now, their research is published in Nature Nanotechnology.
The sound of a single bacterium
Farbod Alijani’s team was originally looking into the fundamentals of the mechanics of graphene, but at a certain point they wondered what would happen if this extremely sensitive material comes into contact with a single biological object. “Graphene is a form of carbon consisting of a single layer of atoms and is also known as the wonder material,” says Alijani. “It’s very strong with nice electrical and mechanical properties, and it’s also extremely sensitive to external forces.”
The team of researchers initiated a collaboration with the nano biology group of Cees Dekker and the nanomechanics group of Peter Steeneken. Together with PhD student Irek Roslon and postdoc Dr. Aleksandre Japaridze, the team ran their first experiments with E. coli bacteria. Cees Dekker: “What we saw was striking! When a single bacterium adheres to the surface of a graphene drum, it generates random oscillations with amplitudes as low as a few nanometers that we could detect. We could hear the sound of a single bacterium!”
Punching a graphene drum with a bacterium
The extremely small oscillations are a result of the biological processes of the bacteria with main contribution from their flagella (tails on the cell surface that propel bacteria). “To understand how tiny these flagellar beats on graphene are, it’s worth saying that they are at least 10 billion times smaller than a boxer’s punch when reaching a punch bag. Yet, these nanoscale beats can be converted to sound tracks and listened to — and how cool is that,” Alijani says.
Graphene for fast detection of antibiotic resistance
This research has enormous implications for the detection of antibiotic resistance. The experimental results were unequivocal: If the bacteria were resistant to the antibiotic, the oscillations just continued at the same level. When the bacteria were susceptible to the drug, vibrations decreased until one or two hours later, but then they were completely gone. Thanks to the high sensitivity of graphene drums, the phenomenon can be detected using just a single cell.
Farbod Alijani: “For the future, we aim at optimizing our single-cell graphene antibiotic sensitivity platform and validate it against a variety of pathogenic samples. So that eventually it can be used as an effective diagnostic toolkit for fast detection of antibiotic resistance in clinical practice.” Peter Steeneken concludes: “This would be an invaluable tool in the fight against antibiotic resistance, an ever- increasing threat to human health around the world.”
Story Source:
Materials provided by Delft University of Technology. Note: Content may be edited for style and length.

Read more →

Newly developed genetic risk scores could help patients, physicians make health decisions

A person’s risk of developing diseases such as type 2 diabetes or breast cancer may be influenced by thousands of genetic differences. Looking at a single DNA difference that has a small effect on risk may not be clinically useful, but when hundreds or thousands of these small risks are added up into a single score, often called a polygenic risk score (PRS), they might offer clinically meaningful information about a person’s disease risk. In a new paper published in Nature Medicine, researchers from Brigham and Women’s Hospital, Veterans Affairs (VA) Boston Healthcare System, and Harvard Medical School developed and validated polygenic risk scores for six common diseases. The team also developed informational resources for each disease to help physicians and patients discuss how to incorporate PRS when making medical decisions about screening and prevention.
“As a primary care physician myself, I knew that busy physicians were not going to have time to take an entire course on polygenic risk scores,” said corresponding author Jason Vassy, MD, MPH, of the Brigham’s Division of General Internal Medicine & Primary Care, the Brigham’s Precision Population Health at Ariadne Labs and VA Boston. “Instead, we wanted to design a lab report and informational resources that succinctly told the doctor and patient what they need to know to make a decision about using a polygenic risk score result in their health care.”
Vassy and colleagues developed the risk scores as part of the Genomic Medicine at VA (GenoVA) Study, a randomized clinical trial of PRS testing among generally healthy adults. The study team developed and validated a laboratory test at the Mass General Brigham Laboratory for Molecular Medicine (LMM) for polygenic risk scores for atrial fibrillation, coronary artery disease, type 2 diabetes, breast cancer, colorectal cancer, and prostate cancer.
The GenoVA Study is currently enrolling patients at the VA Boston Healthcare System, and the investigators reported the results from the first 227 patients, among whom 11 percent were found to have a high polygenic risk score for atrial fibrillation, 7 percent for coronary artery disease, 8 percent for type 2 diabetes, and 6 percent for colorectal cancer. Among men, 15 percent had a high score for prostate cancer, while 13 percent of women had a high score for breast cancer. The GenoVA Study will ultimately enroll more than 1,000 patients and follow them for two years to observe how they and their primary care providers use the polygenic risk scores in clinical care. For example, high-risk patients might choose to undergo screening tests more frequently or take preventive medications that can lower their risk.
The researchers had to address many challenges in implementing a clinical laboratory PRS test. Most importantly, their own observations confirmed a problem that was already known about these scores: they are less accurate in individuals of non-European descent. Most genomic research to date has been conducted in European populations, thus the scores resulting from this research have a weaker ability to predict disease risk among non-European populations. Implementing a polygenic risk score into clinical care that is only accurate for people of European descent would exacerbate existing health disparities. To address this important limitation, the researchers applied additional statistical methods to enable PRS calculation across multiple racial groups.
“Researchers must continue working to increase the diversity of patients participating in genomics research,” said Matthew Lebo, PhD, Chief Laboratory Director at the LMM. “In the meantime, we were heartened to see that we could generate and implement valid genetic scores for patients of diverse backgrounds.”
To date, 52 percent of GenoVA Study enrollees report non-white race and/or Hispanic/Latinx ethnicity.
Another key challenge in bringing polygenic risk score to clinical medicine is that physicians and patients will need support to understand them and use them to make medical decisions. Clinical guidelines do not yet exist to help a physician know whether and how they should treat a patient with a high-risk score differently than an average-risk patient, but the study provides physician- and patient-oriented educational materials to help them incorporate the results. In addition, patients and primary care physicians can seek support from a genetic counselor in the study.
The researchers hope that this first report from the GenoVA Study will be a useful guide for other laboratories and health care systems looking to implement polygenic risk score testing in patient care. “It’s still very early days for precision prevention,” says Vassy, “but we have shown it is feasible to overcome some of the first barriers to bringing polygenic risk scores into the clinic.”
Funding: This work was supported by the NIH National Human Genome Research Institute (R35HG010706) and the NIH (R01HL139731, R01HL157635), American Heart Association (18SFRN34250007), National Heart, Lung and Blood Institute (R01HL142711, R01HL148050, R01HL151283, R01HL127564, R01HL148565, R01HL135242, R01HL151152), National Institute of Diabetes and Digestive and Kidney Diseases (R01DK125782), Fondation Leducq (TNE-18CVD04) and Massachusetts General Hospital (Fireman Chair).

Read more →

Clinicians grapple with decisions in crisis-care simulation

The COVID-19 pandemic has led healthcare organizations to draft plans for critical patient care in the event of shortages of resources such as ventilators. Invoking “crisis-care” standards at a hospital would prompt the deployment of a triage team — three or four seasoned clinicians and a medical ethicist responsible to determine which patients have the best chance of survival and prioritizing these people to receive scarce resources while deprioritizing others.
If this task sounds tragic, you’re in good company: A new analysis conveys the moral distress that triage team members experienced while participating in a simulated crisis-care event in which they had to decide which patients would and would not be prioritized to receive life-sustaining resources.
The paper was published April 18 in JAMA Network Open.
“This was a setting to try to operationalize a process for making life-and-death patient decisions in a way that most medical professionals have never faced before,” said the paper’s lead author, Dr. Catherine Butler. She is an assistant professor of medicine (nephrology) at the University of Washington School of Medicine.
The qualitative analysis was based on interviews conducted from December 2020 to February 2021 with 41 triage-team members from hospitals in Washington state. They had participated in 12 patient simulations and their feedback informed the WA state Department of Health’s guidebook for critical care in response to potential extreme resource scarcity during the pandemic.
The intention of the guidebook, Butler said, is to provide plans based on empirical evidence and community deliberation that would standardize the triage process, improve fairness, and reduce the emotional toil involved in the grave deliberations for which triage team members might be unprepared.

Read more →

A single allele deletion in gene encoding Zbtb38 leads to early embryonic death

DNA methylation is a major epigenetic modification that is crucial for mammalian development. For instance, DNA methylation is central to inexhaustible biological processes, such as gene regulation and cell fate decisions. In mammals, DNA methyltransferases are key for blastocysts to re-establish global DNA methylation patterns during implantation. This is critical for passing on epigenetic information to the next generation. On the other hand, the role of methyl-CpG binding proteins (MBPs) that bind methylated CpG as part of the DNA methylation processes is still unclear. However, a previous study conducted by researchers at Nara Institute of Science and Technology (NAIST), Japan, clarified that; Zbtb38, also known as CIBZ, is a zinc finger type of MBP that is pivotal for the growth of mouse embryonic stem (ES) cells. They further demonstrated that Zbtb38 facilitates the expression of Nanog, which is fundamental for the growth of ES cells. However, what Zbtb38 does in real life, is still a mystery.

advertisement

Read more →

Tumors partially destroyed with sound don't come back

Noninvasive sound technology developed at the University of Michigan breaks down liver tumors in rats, kills cancer cells and spurs the immune system to prevent further spread — an advance that could lead to improved cancer outcomes in humans.
By destroying only 50% to 75% of liver tumor volume, the rats’ immune systems were able to clear away the rest, with no evidence of recurrence or metastases in more than 80% animals.
“Even if we don’t target the entire tumor, we can still cause the tumor to regress and also reduce the risk of future metastasis,” said Zhen Xu, professor of biomedical engineering at U-M and corresponding author of the study in Cancers.
Results also showed the treatment stimulated the rats’ immune responses, possibly contributing to the eventual regression of the untargeted portion of the tumor and preventing further spread of the cancer.
The treatment, called histotripsy, noninvasively focuses ultrasound waves to mechanically destroy target tissue with millimeter precision. The relatively new technique is currently being used in a human liver cancer trial in the United States and Europe.
In many clinical situations, the entirety of a cancerous tumor cannot be targeted directly in treatments for reasons that include the mass’ size, location or stage. To investigate the effects of partially destroying tumors with sound, this latest study targeted only a portion of each mass, leaving behind a viable intact tumor. It also allowed the team, including researchers at Michigan Medicine and the Ann Arbor VA Hospital, to show the approach’s effectiveness under less than optimal conditions.

Read more →

AF2Complex: Researchers leverage deep learning to predict physical interactions of protein complexes

From the muscle fibers that move us to the enzymes that replicate our DNA, proteins are the molecular machinery that makes life possible.
Protein function heavily depends on their three-dimensional structure, and researchers around the world have long endeavored to answer a seemingly simple inquiry to bridge function and form: if you know the building blocks of these molecular machines, can you predict how they are assembled into their functional shape?
This question is not so easy to answer. With complex structures dependent on intricate physical interactions, researchers have turned to artificial neural network models — mathematical frameworks that convert complex patterns into numerical representations — to predict and “see” the shape of proteins in 3D.
In a new paper published in Nature Communications, researchers at Georgia Tech and Oak Ridge National Laboratory build upon one such model, AlphaFold 2, to not only predict the biologically active conformation of individual proteins, but also of functional protein pairings known as complexes.
The work could help researchers bypass lengthy experiments to study the structure and interactions of protein complexes on a large scale, said Jeffrey Skolnick, Regents’ Professor and Mary and Maisie Gibson Chair in the School of Biological Sciences and one of the corresponding authors of the study, adding that computational models such as these could mean big things for the field.
If these new computational models are successful, Skolnick said, “it could fundamentally change the way biological molecular systems are studied.”
Primed for Protein Prediction

Read more →

Some children with cerebral palsy scoliosis may not need pelvic fixation, study shows

A new Michigan Medicine study finds that some children with cerebral palsy and scoliosis do not require pelvic fixation when undergoing growing rod treatment, potentially avoiding several complications.
Using data from around 20 health systems, researchers analyzed nearly 100 pediatric patients with cerebral palsy and scoliosis treated with growth-friendly implants, in which expandable rods are inserted into the back to help control the spinal curvature while still allowing the spine to grow. They found that for children with a pelvic tilt and lower lumbar spine tilt of fewer than 10 degrees, the pelvis did not need to be included when inserting growing rods. The results are published in Spine Deformity.
“Inserting screws into the pelvis to anchor the growing rods is not benign; screws in that area tend to be more prominent,” said G. Ying Li, M.D., lead author of the paper and pediatric orthopaedic surgeon at University of Michigan Health C.S. Mott Children’s Hospital.
“Prominent screws can be painful and can also cause overlying skin breakdown, leading to infection. In the past, there has also been a high rate of these screws failing. For these reasons, understanding which kids have enough of a tilt in their pelvis and lower lumbar spine to benefit from anchoring the rods into the pelvis is important.”
Children with cerebral palsy have abnormal nerve and muscle control, and many of them are wheelchair users. When they develop scoliosis, the curve in their spine tends to be longer and more sweeping than those without the condition. The curve may extend into the pelvis, affecting standing and sitting balance and causing pressure that can make sitting more painful or lead to skin breakdown.
Patients treated with growing rods require more than one surgery, and most children eventually need a spinal fusion. Growth-friendly treatment is already associated with more complications than a single spinal fusion. For patients with cerebral palsy who have a small enough pelvic tilt, Li says, it is beneficial to avoid inserting screws into the pelvis in the early stages of growth-friendly treatment.
“Even though we did see some children with growing rods anchored to the spine who later needed to have the rods anchored to the pelvis, we inserted those pelvic screws when kids were undergoing their final spinal fusion procedure,” she said.
“These findings provide fellow surgeons with more information to help patients avoid complications while still correcting a curve that can impact quality of life, pain and lung development for children with cerebral palsy.”
Story Source:
Materials provided by Michigan Medicine – University of Michigan. Original written by Noah Fromson. Note: Content may be edited for style and length.

Read more →

'I felt more joy than I thought possible'

SharecloseShare pageCopy linkAbout sharingImage source, Science Photo Library”I had the full-blown mystical revelatory experience – the big psychedelic multi-coloured light and sound show.” This is how Steve recalls his first dose of a hallucinogenic drug, psilocybin, the psychedelic compound found in magic mushrooms. His experience was part of a clinical trial that some scientists are calling a major step towards a revolution in the treatment of depression. It is a trial complicated by the fact that the drug it is testing is illegal. Psilocybin is a Schedule 1 controlled substance; its use is very strictly regulated. Part of the definition of a Schedule 1 drug is that it is not used medicinally. But this trial, which scanned of the brains of participants after their treatment with psychedelics, painted an extraordinary physical picture of the effect and the experience. The brain scans showed “more connectivity” between different brain regions. The researchers say their findings show how hallucinogenics break a depressed person “out of a rut of negative thinking” – that psilocybin “reintegrates” a depressed brain, making it more fluid, flexible and connected. So how does it feel to have your brain reintegrated by psychedelic drugs? Image source, Jane Heritage”It’s an ineffable experience – words like the ones we’re using now are just not enough,” Steve told BBC Radio 4’s Inside Science.”With the first dose, I felt joy like I’ve never experienced – and more like myself than I’ve ever felt.” But the second dose in the trial, he said, was very dark.Steve, who is now in his 60s, was diagnosed with depression more than 30 years ago.Traditional antidepressants simply did not work for him. Those existing drugs work by increasing the levels of a chemical called serotonin in the brain. That is one of the chemical messengers that relays signals from one part of the brain to another; low serotonin has been associated with depression since the 1960s. Image source, Jane HeritageBut while antidepressant drugs that “correct” that serotonin imbalance numbed the lows for Steve – lows that he said could often make him feel that his life was completely worthless – they also numbed the highs. “[When I was taking those drugs] there was just no colour – no joy in my life. “You end up living like a functional zombie.”Steve made the difficult decision to come off the drugs. He continued his long-term regime of meditation, yoga and running that he says has helped him to manage his depression all these years. But when he heard an interview on the radio about a new trial investigating the use of psychedelics for depression, he called to volunteer. “I had to wait a year, and selection criteria were very tough.” Participants had to show, not only that other antidepressants had not been successful in treating their depression, but that they did not have other conditions, including psychosis, that could make the use of psychedelics particularly risky. Finally, after careful vetting, and under the supervision of a professional therapist, Steve was given his first dose of psilocybin.”It felt wonderful,” he recalled. “I felt more connected to myself – it was extraordinary. Image source, Emily Walker”It took from not knowing myself at all to having a sense of what my place was in the greater scheme of things.”What Steve felt has shown up in brain scans. Images of participants’ brains before and after a dose of “magic mushroom juice” showed what lead researcher Prof David Nutt, from the Imperial Centre for Psychedelic Research, described as a brain reset. The images showed that psychedelics induced a connectivity, where different brain regions communicated with each other much more, revealing new ways of thinking. “I had no conscious sense of my brain being ‘scrambled’ but certainly there was a lot more going on there than I could ever have imagined,” said Steve. His second experience with psilocybin though, was much more difficult. “I had to wrestle with those feelings and emotions that I tend to suppress. “So, the second session, although it was hard work, was probably therapeutically more useful, because I had to deal with the stuff that I that I just hadn’t dealt with before. Prof Nutt is campaigning for these illegal drugs to be reclassified for research purposes, in order to make trials like his less legally complicated – and to enable what he says could be a revolution in the treatment of depression. Image source, Getty ImagesBut the drug, both Steve and Prof Nutt stressed, is no magic antidepressant bullet. In the trial, the treatment was combined with professional therapy. Ongoing work at the Centre for Psychedelic Research, and elsewhere, is focused on developing and safely testing new therapeutic protocols, ways to combine drug treatment with therapy in order to treat depression in a new way. “The drug gives us part of a healing process. It exposes you to different possibilities – another way of being,” said Steve. The real work, he says, starts after the experience and needs the guidance of a therapist to make it meaningful. “It’s one thing developing a drug, but we need protocols to help people like me,” said Steve. “But I would not change the experience for anything – it was wonderful – and I don’t expect ever to experience anything like it again.” Hear Steve’s interview with Victoria and more about the psychedelic drug trial on BBC Inside Science on BBC Sounds.More on this storyPsychedelic frees up depressed brain, study showsPM to consider calls to legalise magic mushroom drug

Read more →